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ABSTRACT
Epidemiological studies have demonstrated that the genetic component is an important risk 
factor for the development of schizophrenia. The genes that codify the different compounds 
of the dopaminergic system have created interest for molecular investigations in patients 
with schizophrenia because the antipsychotic drugs, especially those of first generation, act 
on this cerebral system. Thus the aim of the present study was to investigate the possible 
association between a new single nucleotide polymorphism (rs6347) located in exon 9 of 
the protein transporter (SLC6A3) and schizophrenia. The distribution of the alleles and 
genotypes of the studied polymorphism was investigated in a sample of 235 patients and 
834 controls matched by gender and age. There were statistical differences in the allelic 
(c2=5.97, 1d.f., p=0.01, OR=1.33–1.05<OR<1.69) and genotypic (c2=6.56, 2d.f., p=0.03) 
distributions between patients and controls. Thus the SLC6A3 A1343G polymorphism was 
associated to the SCZ phenotype in the investigated sample.
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RESUMO
Estudos epidemiológicos têm demonstrado que o componente genético é um importante 
fator de risco para a esquizofrenia. Os genes que codificam os diferentes componentes 
do sistema dopaminérgico passaram a despertar interesse para estudos moleculares em 
pacientes com esquizofrenia, pois os antipsicóticos, em especial os de primeira geração, 
exercem sua ação nesse sistema. Assim, o objetivo do presente estudo foi investigar a 
associação entre um novo polimorfismo de nucleotídeo único (rs6347) localizado no exon 
9 do gene do transportador de dopamina (SLC6A3) e esquizofrenia. Um total de 235 
pacientes e 834 controles pareados para sexo e idade foi selecionado para a investigação 
da distribuição dos alelos e genótipos do polimorfismo investigado entre os grupos de 
pacientes e controles. Houve diferenças estatisticamente significantes nas distribuições 
alélicas (c2=5,97, 1d.f., p=0,01, OR=1,33–1,05<OR<1,69) e genotípicas (c2=6,56, 2d.f., 
p=0,03) entre pacientes e controles. Assim, o polimorfismo SLC6A3 A1343G mostrou 
associação com esquizofrenia na amostra estudada.
Palavras-chave: estudo de associação, dopamina, transportador de dopamina, genética, 
psicose.
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Schizophrenia (SCZ) is a psychiatric 
disorder characterized by psychotic symp-
toms, alterations of thought, affect, voli-
tion and behavior and affects some 1% of 
the general population. Genetic epidemi-
ological investigations have suggested that 
there is an important participation of a ge-
netic component on the etiology of SCZ 
and heritability estimates as high as 80% 
have been reported1. The mode of inheri-
tance is complex showing a polygenic-en-
vironmental interaction. The role of a sin-
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gle relevant gene must be small, thus association stud-
ies, involving case-control approaches, have been per-
formed to evaluate the allelic variations at specific can-
didate genes which may be related to the etiopathology 
of the disorder2.
Some of the most investigated genes in studies of vul-
nerability to SCZ are those that code for proteins of the 
dopaminergic system because the evidences of the role of 
central dopamine pathways in the pathophysiology of the 
disorder3-5. Stimulant drugs, that block reuptake of dop-
amine or facilitate its release on neuronal synapses, may 
induce psychotic symptoms6. L-DOPA has also been re-
lated to psychotic symptoms through variable release of 
dopamine into the synapse6. Some antipsychotic drugs 
correlate their efficacy with their action at dopaminergic 
receptors7. Therefore, genes involved in the dopaminer-
gic system are potential targets for genetic association in-
vestigations with SCZ.
Polymorphisms in dopamine receptors genes have 
been widely investigated as risk factors for SCZ develop-
ment, however the results have been inconclusive3-5. An-
other possible candidate for such investigations is the do-
pamine transporter gene (SLC6A3 or DAT1). The dop-
amine transporter plays an important role in the regula-
tion of dopamine levels and neurotransmission by medi-
ating the active re-uptake of synaptic dopamine back into 
the neurons8. Two post-mortem studies on SLC6A3 bind-
ing and SCZ showed decreased striatal SLC6A3 density 
in chronic SCZ9,10. A recent study using positron emis-
sion tomography found lower SLC6A3 density in sites in 
the basal ganglia, particularly in the middle third of pu-
tamen, in chronic SCZ patients than controls. This may 
suggest a decreased expression of SLC6A3 in a subset of 
chronic SCZ patients11.
The SLC6A3 was cloned and mapped to human chro-
mosome 5 (5p15.3)12. A new single nucleotide polymor-
phism (SNP) was identified in exon 9 of the SLC6A3 
(rs6347)13. There is an A1343G substitution, however this 
is a synonymous polymorphism and there is no amino-
acide change (Ser/Ser). As far as we know the present 
study is the first one investigating the SLC6A3 A1343G 
polymorphism as a risk factor for SCZ development.
METHOD
Sample
Our sample was consisted of 235 (male=152: 64.68%; 
female=83: 35.32%) Brazilian SCZ patients, and recruit-
ed at the Institute of Psychiatry, Hospital das Clínicas, 
University of São Paulo Medical School. The diagnosis of 
SCZ was made according to the Diagnostic and Statistical 
Manual of Mental Disorders - Fourth Edition (DSM-IV)14 
criteria, based on a clinical interview conducted by a psy-
chiatrist. A total of 834 (male=520: 62.35%; female=314: 
37.65%) healthy control subjects were selected from un-
related subjects admitted to the Blood Donation Center 
of the Fundação Pró-Sangue of the University of São Pau-
lo Medical School.
All patients and control subjects provided written in-
formed consent for taking blood samples. Ethical approv-
al for the study was obtained from the Ethics Commit-
tee at the Hospital das Clínicas, University of São Paulo 
Medical School (CAPPesq).
DNA extraction
Blood samples (10 mL) were collected from all partic-
ipants of the study, and DNA was extracted from leuko-
cytes using the “salting out” protocol15.
Genotyping
Genotyping of the investigated polymorphism for this 
study was performed blind to the clinical status of the in-
dividuals according to Greenwood et al.13 and Guindali-
ni et al.16.
To avoid errors, genotyping was read by two indepen-
dently trained research technicians. When a disagreement 
arose the genotyping was repeated. In addiction, random 
re-genotyping was repeated in 20% of the sample.
Statistical analysis
The statistical power of the sample was evaluated us-
ing the CaTS Program (Center for Statistical Genetics – 
The University of Michigan) (http://www.sph.umich.edu/
csg/abecasis/CaTS/index.html).
A test for deviations from the Hardy-Weinberg equi-
librium was performed using the HWE program17.
Allelic and genotypic distributions of the SLC6A3 
A1343G polymorphism were compared between 235 pa-
tients and 834 healthy controls. Chi-square test, used to 
investigate possible association between genotypes and 
alleles with SCZ, was performed by the EpiInfo version 
6.0. Chi-square test was also used to investigate difference 
between gender distribution between the groups of pa-
tients and controls. Differences of age between the inves-
tigated groups were analyzed using student’s t-test.
For all statistic tests the level of significance adopted 
was α<0.05 or 5%.
RESULTS
The power of the sample, based on 235 patients and 
834 controls, disorder prevalence of 1%, average allel-
ic frequency around 20%, multiplicative model with the 
genotype relative risk=1.5 and significance level of 0.05, 
was 97%.
There were no significant deviations from Hardy-
Weinberg equilibrium in the patients (p=0.28) and controls 
(p=0.69) samples for the SLC6A3 A1343G polymorphism.
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For patients, mean age was 28.3±6.9 years (19-64) and 
median age was 26.4 years. For controls, mean age was 
31.2±8.3 years (18-79) and median age was 29.1 years 
There was no statistical difference related to age between 
the groups of patients and controls (p=0.21). Statisti-
cal analysis did not evidence difference related to gen-
der distribution between the groups investigated as well 
(c2=0.43; p=0.51).
There were statistical differences in the allelic (c2=5.97, 
1d.f., p=0.01, OR=1.33–1.05<OR<1.69) and genotypic 
(c2=6.56, 2d.f., p=0.03) distributions between patients 
and controls (Table).
DISCUSSION
Findings of post-mortem and neuroimaging stud-
ies have suggested that SLC6A3 may play a role in the 
pathophysiology of SCZ9-11. The evidences of involve-
ment of the dopaminergic system in the pathophisiolo-
gy of SCZ have collaborated to the investigation of ge-
netic polymorphisms of this cerebral pathway on such 
disorder. There are previous studies that investigated the 
role of different SLC6A3 polymorphisms as risk factors 
for SCZ development4 however to our knowledge this is 
the first investigation to perform an association study be-
tween the SLC6A3 A1343G polymorphism and such dis-
order. This is a synonymous polymorphism and it does 
not promote a change of amino acids (Ser/Ser)13. How-
ever the investigation of synonymous polymorphisms is 
important because they may in linkage disequilibrium 
with another polymorphism on SLC6A3 which is a gene 
of interest for SCZ research. Moreover recent study has 
demonstrated that synonymous polymorphisms may al-
ter gene translation. Duan et al. found that some synony-
mous mutations in the human DRD2 gene have function-
al effects, alter the predicted mRNA folding, led to a de-
crease in mRNA stability and translation, and dramatical-
ly change dopamine-induced up-regulation of DRD2 ex-
pression, indicating that synonymous variations can have 
effects on pathophysiological aspects of psychiatric dis-
orders such as SCZ18.
As the investigated polymorphism may be in linkage 
disequilibrium with another polymorphism on SLC6A3 
which could influence the risk for the SCZ, it could be 
premature to assess the validity of the association found 
in the present work. Moreover in populations of high-
ly admixed ethnicity like the Brazilian one, we may face 
problems about ethnical stratification19-21. Physical phe-
notype in Brazil is not an adequate predictor of genomic 
ancestry what difficult the ethnical matching in case-con-
trols studies22. However the fact that the present sample 
(patients and controls) is in Hardy-Weinberg equilibrium 
indicates that our sample may not have important prob-
lems regarding population stratification23. It is also impor-
tant to note that ethnical matching conducted using ge-
netic markers was performed in part of our sample in a 
case-control study with cocaine dependence and the re-
sults showed that, despite the ethnic admixture in Brazil, 
the ethnic stratification was not a bias in that case24.
In conclusion, the results of the present investigation 
provide evidence for the association between the poly-
morphism SLC6A3 A1343G polymorphism and SCZ in 
our Brazilian sample. However to confirm the associa-
tion of this polymorphism with SCZ further studies must 
be conducted focusing on ethnical aspects. It is always 
important to consider the possibility that the investigat-
ed polymorphism is in linkage disequilibrium with non-
identified genes that are in fact those contributing to the 
pathogenesis of SCZ or even with other polymorphisms 
within the SLC6A3 therefore more comprehensive poly-
morphisms coverage within the SLC6A3 is warranted. 
The genetic association found in the present work could 
be clarified by the analysis of larger case-control stud-
ies, additional family-based studies, and especially link-
age disequilibrium mapping of SLC6A3, which should be 
Table. Distributions of the SLC6A3 A1343G alleles and genotypes frequencies in SCZ patients and 
controls samples.
Polymorphism Cases (%) Controls (%) c2 d.f. p
Genotypes
   A/A 132 (56.17) 393 (47.12)
6.56 2 0.03
   A/G 84 (35.74) 356 (42.69)
   G/G 19 (8.09) 85 (10.19)
   Total 235 (100) 834 (100)
Alleles
   A 348 (74.04) 1142 (68.47)
5.97 1 0.01   G 122 (25.96) 526 (31.53)
   Total 470 (100) 1668 (100)
c2: Chi-square test; DF: degrees of freedon; P: probability.
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considered an important gene given its potential impor-
tant influence on the risk for SCZ development.
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